FDA approves telavancin

FDA approved an NDA from Theravance Inc. (NASDAQ:THRX) and Astellas Pharma Inc. (Tokyo:4503) for Vibativ telavancin to treat complicated skin and skin structure infections (cSSSIs) caused by susceptib...